Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2413 • 2019 ACR/ARP Annual Meeting
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjoegren’s Syndrome
Bruno Cenni¹, Peter End ¹, Maciej Cabanski ¹, Annamaria Jakab ¹, Enrico Funhoff ¹, Magdalena Kistowska ¹, Arvind Kinhikar ², Alessio Maiolica ¹, Masaru Hirano ³, Barbara Nuesslein-Hildesheim ¹, Amanda Littlewood-Evans ¹, Daniela Angst ¹, Robert Pulz ⁴ and Martin Kaul ¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Novartis Institutes for BioMedical Research, Cambridge, MA, ³Novartis Institutes for BioMedical Research, Tokyo, Japan, ⁴Novartis Institues for BioMedical Research, Basel, Switzerland
Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a cytoplasmic tyrosine kinase selectively expressed in B cells, macrophages, mast cells and basophils. The essential role of BTK…
Abstract Number: 2432 • 2019 ACR/ARP Annual Meeting
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS) and Related Lymphoma: Results in Independent Cohorts
Saviana Gandolfo¹, Cinzia Fabro ¹, Serena Colafrancesco ², Francesco Carubbi ³, Francesco Ferro ⁴, Elena Bartoloni ⁵, Efstathia Kapsogeorgou ⁶, Andreas Goules ⁶, Luca Quartuccio ¹, Roberta Priori ², Alessia Alunno ⁵, Guido Valesini ², Roberto Giacomelli ³, Roberto Gerli ⁵, Chiara Baldini ⁴, Athanasios Tzioufas ⁶ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ²Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy, Roma, Italy, ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Science, School of Medicine, University of L'Aquila, L'Aquila, Italy, L'Aquila, Italy, ⁴Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy, Perugia, Italy, ⁶Department of Pathophysiology, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece
Background/Purpose: Thymic stromal lymphopoietin (TSLP) has been implicated in primary Sjögren’s syndrome (pSS) and related B-cell lymphoproliferation / lymphoma (NHL) by tissue studies on salivary…
Abstract Number: 1453 • 2019 ACR/ARP Annual Meeting
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Eun Hye Park¹, You-Jung Ha ¹, Eun Ha Kang ¹, Yeong-Wook Song ² and Yun Jong Lee ³, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Hospital, Seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea
Background/Purpose: The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) and EULAR SS Patient-Reported Index (ESSPRI) have been validated as disease activity and outcome measures…
Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Jolien van Nimwegen¹, Esther Mossel ¹, Robin Wijnsma ¹, Greetje van Zuiden ¹, Konstantina Delli ¹, Alja Stel ¹, Bert van der vegt ¹, Erlin Haacke ¹, Lisette Olie ¹, Leonie Los ¹, Gwenny Verstappen ¹, Sarah Pringle ¹, Fred Spijkervet ¹, Frans Kroese ¹, Arjan Vissink ¹, Suzanne Arends ² and Hendrika Bootsma ³, ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Dept. of Rheumatology and Clinical Immunology - University Medical Center Groningen (UMCG), University of Groningen, Groningen, Netherlands, ³University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…
Abstract Number: 2433 • 2019 ACR/ARP Annual Meeting
Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
Saviana Gandolfo¹, Marco Binutti ¹, Elena Doriguzzi Breatta ¹, Cinzia Fabro ¹ and Salvatore De Vita ¹, ¹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy
Background/Purpose: Fatigue is one of the most prevalent and impacting symptoms in primary Sjögren’s syndrome (pSS), significantly impairing the patient quality of life. To date,…
Abstract Number: 1454 • 2019 ACR/ARP Annual Meeting
Sjӧgren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms
Sara McCoy¹, Christie Bartels ², Esen Akpek ³, Ian Saldanha ⁴, Vatinee Bunya ⁵, Matthew Makara ⁶ and Alan Baer ⁷, ¹University of Wisconsin School of Medicine and Public Health, Madison, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Johns Hopkins University, Baltimore, ⁴Brown University School of Public Health, Providence, RI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Sjogren's Syndrome Foundation, Reston, VA, ⁷Johns Hopkins University, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) is the second most common systemic autoimmune disease, typically characterized by ocular and oral sicca. SS is associated with reduced quality…
Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2434 • 2019 ACR/ARP Annual Meeting
Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Joong Kyong Ahn ¹, Jiwon Hwang² and Gi Hyeon Seo ³, ¹Division of Rheumatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon-si, Republic of Korea, ³Health Insurance Review and Assessment Service, Wonju, Republic of Korea
Background/Purpose: The development of lymphomas is one of the most serious complications of SjS but the incidence, prevalence and estimated risk of lymphoma in primary…
Abstract Number: 1463 • 2018 ACR/ARHP Annual Meeting
Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?
Evo Alemao¹, Yogesh Saini², Ying Bao¹, Aarti Rao², Christine K Iannaccone³, Michelle Frits³, Michael E Weinblatt³ and Nancy A. Shadick³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Mu Sigma, Bangalore, India, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered an extra-articular manifestation of RA and is an autoantibody-mediated condition similar to RA. Thus, patients (pts) with sSS…
Abstract Number: 1580 • 2018 ACR/ARHP Annual Meeting
Persistent Serological Activity in Primary Sjögren’s Syndrome
Jorge Lopez-Morales, Daniel Cortes-Muñoz and Gabriela Hernandez-Molina, Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición SZ, Mexico City, Mexico
Background/Purpose: To assess presence of persistent serological activity and its association with clinical outcomes in a cohort of patients with primary Sjögren’s syndrome (pSS). Methods:…
Abstract Number: 2881 • 2018 ACR/ARHP Annual Meeting
How Immunological Profile Drives Clinical Phenotype of Primary Sjögren’s Syndrome at Diagnosis: Analysis of 10.500 Patients (Sjögren Big Data Project)
Soledad Retamozo^1,2, Nihan Acar-Denizli³, Wan-Fai Ng⁴, Margit Zeher⁵, Astrid Rasmussen⁶, Thomas Mandl⁷, Raphaele Seror⁸, Xiaomei Li⁹, Chiara Baldini¹⁰, Jacques-Eric Gottenberg¹¹, Debashish Danda¹², Luca Quartuccio¹³, Roberta Priori¹⁴, Gabriela Hernandez-Molina¹⁵, Berkan Armagan¹⁶, Aike A. Kruize¹⁷, Seung-Ki Kwok¹⁸, Marika Kvarnström¹⁹, Sonja Praprotnik²⁰, Damien Sène²¹, Elena Bartoloni²², Roser Solans²³, Maureen Rischmueller²⁴, Yasunori Suzuki²⁵, David A. Isenberg²⁶, Valeria Valim²⁷, Piotr Wiland²⁸, Gunnel Nordmark²⁹, Guadalupe Fraile³⁰, Hendrika Bootsma³¹, Takashi Nakamura³², Roberto Giacomelli³³, Valérie Devauchelle-Pensec³⁴, Andreas Knopf³⁵, Michele Bombardieri³⁶, Virginia Fernandes Trevisani³⁷, Daniel S. Hammenfors³⁸, Sandra G Pasoto³⁹, Tamer A. Gheita⁴⁰, Fabiola Atzeni⁴¹, Jacques Morel⁴², Cristina Vollenveider⁴³, Ildiko-Fanny Horvath⁵, Kathy L. Sivils⁴⁴, Peter Olsson⁴⁵, Salvatore De Vita⁴⁶, Jorge Sánchez-Guerrero⁴⁷, Levent Kilic¹⁶, Marie Wahren-Herlenius⁴⁸, Xavier Mariette⁸, Manuel Ramos-Casals⁴⁹ and Pilar Brito-Zerón^50,51, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ³Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey, Istanbul, Turkey, ⁴Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, Newcastle, United Kingdom, ⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ⁷Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, ⁸Rheumatology department, Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique- Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, Paris, France, ⁹Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei., Hefei, China, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Rhumatologie, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ¹²Clinical Immunology & Rheumatology, Christian Medical College, Vellore, India, Vellore, India, ¹³Clinic of Rheumatology, Department of Medical Area (DAME), University Hospital “Santa Maria della Misericordia”, Udine., Udine, Italy, ¹⁴Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome., Rome, Italy, ¹⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ¹⁶Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁷Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁸Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul., Seoul, Korea, Republic of (South), ¹⁹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²⁰Department of Rheumatology, University Medical Centre, Ljubljana., Ljubljana, Slovenia, ²¹Lariboisière Hospital, Paris Diderot University, Paris, France, ²²Rheumatology Unit, University of Perugia, Perugia, Italy, ²³Department of Internal Medicine, Hospital Vall d’Hebron, Barcelona, Barcelona, Spain, ²⁴The Queen Elizabeth Hospital and University of Adelaide, Adelaide, Australia, ²⁵Ishikawa, Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Ishikawa, Ishikawa, Japan, ²⁶Centre for Rheumatology Research, University College Hospital London, UK, London, United Kingdom, ²⁷Department of Medicine, Federal University of Espírito Santo and University Hospital HUCAM/EBSERH, Vitória, Vitoria, Brazil, ²⁸Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Wroclaw, Poland, ²⁹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ³⁰Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Madrid, Spain, ³¹Department of Rheumatology & Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands, ³²Department of Radiology and Cancer Biology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³³Clinical Unit of Rheumatology, University of l’Aquila, School of Medicine, L’Aquila, L’Aquila, Italy, ³⁴Rheumatology Department, Brest University Hospital, Brest, Brest, France, ³⁵Otorhinolaryngology/ Head and Neck Surgery, Klinikum rechts der Isar, Technical University Munich, Munich, Germany, ³⁶Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ³⁷Federal University of São Paulo, São Paulo, Brazil, ³⁸Department of Rheumatology, Haukeland University Hospital, University of Bergen, Bergen, Norway, ³⁹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴⁰Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt, ⁴¹IRCCS Galeazzi Orthopaedic Institute, Milan, and Rheumatology Unit, University of Messina, Messina, Italy, ⁴²Department of Rheumatology, Montpellier University Hospital and University of Montpellier, Montpellier, France, ⁴³German Hospital, Buenos Aires, Buenos Aires, Argentina, ⁴⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, ⁴⁵Department of Rheumatology, Skane University Hospital Malmö, Lund University, Malmö, Malmö, Sweden, ⁴⁶Clinic of Rheumatology, Department of Medical Area (DAME), University Hospital “Santa Maria della Misericordia”, Udine, Udine, Italy, ⁴⁷Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, Mexico, Mexico, ⁴⁸Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁴⁹University of Barcelona, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵⁰Sjögren’s Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Bercelona, Spain, ⁵¹Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA Sanitas, Barcelona, Barcelona, Spain
Background/Purpose: To evaluate the influence of the main immunological markers on the disease phenotype at diagnosis in a large international cohort of patients with primary…
Abstract Number: 1468 • 2018 ACR/ARHP Annual Meeting
Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom
Maria Florencia Rodriguez¹, Cristian Troitiño², Emmanuel Guerra³, Fernando Melo⁴, Anastasia Secco⁵, Natalia Tamborenea³, María Victoria Martire⁶ and Marta Mamani⁴, ¹Reumatologia, Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ²Reumatologia, Hospital Bernardino Rivadavia, CAPITAL FEDERAL, Argentina, ³Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁴Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁵Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ⁶Instituto Médico Platense, La Plata, Argentina
Background/Purpose: Secondary Sjögren's Syndrome (sSS) is a common extraarticular manifestation in patients with Rheumatoid Arthritis (RA). According to the 2002 European American criteria (EA 2002)…
Abstract Number: 1581 • 2018 ACR/ARHP Annual Meeting
Lack of Specificity in Testing for Murine Tissue Specific Autoantibodies for the Diagnosis of Sjogren’s Syndrome
Frederick B Vivino¹, Michael D. George², Chadwick Johr³, Nora Sandorfi⁴, Vatinee Bunya⁵, Giacomina Massaro-Giordano⁵, Andrew Diederich⁶, Brandon Eilberg⁶, Lakshmanan Suresh⁷ and Long Shen⁷, ¹Rheumatolgy Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁵Ophthalmology, University of Pennsylvania, Philadelphia, PA, ⁶Orthopedic Surgery, University of Pennsylvania, Philadelphia, PA, ⁷Trinity Biotech, Inc., Buffalo, NY
Background/Purpose: A group of murine parotid tissue specific autoantibodies (TSAs) which includes anti-SP1 (salivary protein 1), anti-PSP (parotid secretory protein) and anti-CA6 (carbonic anhydrase) are…
Abstract Number: 2882 • 2018 ACR/ARHP Annual Meeting
Minimal Progression of Disease Manifestation in Patients with Sjögren’s Syndrome Re-Evaluated Multiple Years after Initial Disease Classification
Astrid Rasmussen¹, Lida Radfar², Kimberly Hefner³, David M. Lewis⁴, C. Erick Kaufman⁵, Donald U. Stone⁶, Kerry M. Leehan¹, Kiely Grundahl⁷, Christopher J. Lessard¹, A. Darise Farris⁸, R. Hal Scofield⁹ and Kathy L. Sivils¹⁰, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ³Hefner Eye Care Center, Oklahoma City, OK, ⁴Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁵Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ⁶Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁷Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ⁸Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Classical connective tissue diseases, such as SLE and RA have well documented progression of disease and damage accrual. However, the natural history of Sjögren’s…
Abstract Number: 1557 • 2018 ACR/ARHP Annual Meeting
Visualization of Dorsal Root Ganglionitis with Three-Tesla Magnetic Resonance Neurography in Sensory Ataxic Neuropathy Associated with Sjögren’s Syndrome
Takeshi Yoshida¹, Takeshi Sueyoshi², Mitsuyo Kinjo³, Shugo Suwazono⁴ and Hiroyuki Nodera⁵, ¹Rheumatology, Chikamori Hospital, Kochi, Japan, ²Radiology, Minei Daiichi Hospital, Urasoe, Japan, ³Rheumatology, Okinawa Chubu Hospital, Uruma, Japan, ⁴Brain-Nerve-Muscle Research Center, National Hospital Organization Okinawa Hospital, Uruma, Japan, ⁵Neurology, Tokushima University School of Medicine, Tokushima, Japan
Background/Purpose: Sjögrenfs syndrome (SS)-associated neuropathy manifests as various forms of neuropathy, including sensory ataxic neuropathy (SAN). Dorsal root ganglionitis, pathologically defined as the lymphocytic infiltration…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].